---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-055028"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2023-05-02T23:59:59+00:00"
generated_at: "2026-06-16T02:29:14.922140+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rigel Pharma Q1 net loss narrows to $13.5M; TAVALISSE sales up 38% to $22.3M

## Summary
- Net loss of $13.5M ($0.08/sh) improved from $27.4M ($0.16) in Q1 2022.
- Total revenue $26.1M: TAVALISSE $22.3M (+38% YoY), REZLIDHIA $1.5M (first full quarter).
- Shipped 2,256 TAVALISSE bottles to patients (highest quarter); 109 REZLIDHIA bottles shipped.
- Accessed $20M term loan from MidCap; cash and investments $58.7M as of March 31.
- Partner Kissei launched TAVALISSE in Japan; Lilly to begin Phase 2a trial of R552 in RA in Q2 2023.

## SEC filing metadata
- accession: 0001104659-23-055028
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2023-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000110465923055028/0001104659-23-055028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000110465923055028/tm2314346d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-055028
- JSON: https://secwatch.observer/filing/0001104659-23-055028.json
- Plain text: https://secwatch.observer/filing/0001104659-23-055028.txt

## Key facts
- Earnings Releases
  RIGEL PHARMACEUTICALS INC reported financial results for first quarter ended March 31, 2023.
  - Period: first quarter ended March 31, 2023
  - Result: reported results
  source text: On May 2, 2023, Rigel Pharmaceuticals, Inc. (“Rigel”) announced certain financial results for its first quarter ended March 31, 2023. A copy of Rigel’s press release, titled “Rigel Reports First Quarter 2023 Financial Results and Provides Business Update,” is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1034842/000110465923055028/0001104659-23-055028-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.